Supernus Showcases The Results From Phase2 Trial Of SPN-820 In Adults With Treatment-Resistant Depression (TRD) x`

Supernus Pharmaceuticals, a biopharmaceutical firm, focused on evolving and marketing CNS therapies. The company today revealed their Phase 2b study of SPN-820 in treating adults with treatment-resistant depression (TRD) failed to demonstrate statistical significance across its principal measurement. The research evaluated the Montgomery-Åsberg Depression Rating Scale  MADRS) total score changes during week 4 yet did not establish any noteworthy distinctions between SPN-820 and the placebo group.

Jack Khattar, President and CEO of Supernus, said in a statement, “We are disappointed that the trial did not meet its primary endpoint in this patient population. We will continue to analyze these data and discuss the future of the program with our development partner, Navitor Pharmaceuticals. I’d like to thank the patients, coordinators and investigators, as well as the development team at Supernus, for their time and efforts in conducting this trial.”

The secondary assessment findings confirmed minimal variations between SPN-820 and placebo treatment. Across the clinical trials, the drug maintained its safe profile similar to previous trials by showing minimal negative side effects to patients.

Supernus Pharmaceuticals continues its CNS disease research activities while examining possibilities for SPN-820 despite its lack of efficacy.